Article
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.
Nature communications - 10 Aug 2018
Arasada Rajeswara Rao, Shilo Konstantin, Yamada Tadaaki, Zhang Jianying, Yano Seiji, Ghanem Rashelle, Wang Walter, Takeuchi Shinji, Fukuda Koji, Katakami Nobuyuki, Tomii Keisuke, Ogushi Fumitaka, Nishioka Yasuhiko, Talabere Tiffany, Misra Shrilekha, Duan Wenrui, Fadda Paolo, Rahman Mohammad A, Nana-Sinkam Patrick, Evans Jason, Amann Joseph, Tchekneva Elena E, Dikov Mikhail M, Carbone David P
Abstract excerpt
EGFR tyrosine kinase inhibitors cause dramatic responses in EGFR-mutant lung cancer, but resistance universally develops. The involvement of β-catenin in EGFR TKI resistance has been previously reported, however, the precise mechanism by which β-catenin activation contributes to EGFR TKI resistance is not clear. Here, we show that EGFR inhibition results in the activation of β-catenin signaling in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.